Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been assigned an average recommendation of “Buy” from the twenty-two analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $102.58.
A number of research analysts have recently issued reports on the company. Credit Suisse Group assumed coverage on Neurocrine Biosciences in a report on Monday, May 20th. They issued an “outperform” rating and a $95.00 target price on the stock. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Zacks Investment Research lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. JPMorgan Chase & Co. raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $100.00 to $106.00 in a report on Monday, April 22nd. Finally, ValuEngine lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Monday, April 15th.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 1,300 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $80.03, for a total value of $104,039.00. Following the sale, the insider now owns 143,276 shares of the company’s stock, valued at $11,466,378.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Haig P. Bozigian sold 19,297 shares of the company’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $85.02, for a total value of $1,640,630.94. Following the completion of the sale, the insider now directly owns 161,273 shares in the company, valued at approximately $13,711,430.46. The disclosure for this sale can be found here. Insiders sold 139,297 shares of company stock worth $11,094,745 in the last three months. 4.30% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of NBIX. Kore Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences in the first quarter valued at $29,000. Acadian Asset Management LLC purchased a new position in Neurocrine Biosciences during the fourth quarter worth about $32,000. Exane Derivatives lifted its position in Neurocrine Biosciences by 48,400.0% during the fourth quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares during the period. Golden State Wealth Management LLC purchased a new position in Neurocrine Biosciences during the first quarter worth about $44,000. Finally, Quadrant Capital Group LLC lifted its position in Neurocrine Biosciences by 9,242.9% during the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock worth $56,000 after buying an additional 647 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.
Shares of NASDAQ:NBIX traded up $2.05 during trading on Thursday, reaching $84.21. The company had a trading volume of 561,269 shares, compared to its average volume of 948,220. The firm has a market cap of $7.56 billion, a P/E ratio of 382.77 and a beta of 1.45. The company has a current ratio of 8.79, a quick ratio of 8.61 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $126.98.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.07). The company had revenue of $138.40 million during the quarter, compared to analyst estimates of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The company’s revenue for the quarter was up 94.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.47) EPS. Research analysts forecast that Neurocrine Biosciences will post -0.08 EPS for the current fiscal year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: Bollinger Bands
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.